Jun 01, 2021 / 12:30PM GMT
Operator
Greetings, and welcome to Alkermes Conference Call to discuss the approval of LYBALVI. My name is Devin, and I will be your conference operator for today. (Operator Instructions)
Please note, this conference is being recorded. I would now like to turn the conference over to your hopes Sandy Coombs, Vice President of Investor Relations. Thank you, Sandy. You may begin.
Sandra Coombs - Alkermes plc - Co-Head of IR
Good morning. Welcome to the Alkermes plc Conference Call to discuss the FDA approval of LYBALVI for the treatment of schizophrenia and bipolar I disorder.
With me today are Richard Pops, our CEO; Blair Jackson, our Chief Operating Officer; and Todd Nichols, our Chief Commercial Officer. Our Chief Medical Officer, Craig Hopkinson, will also join us for the Q&A.
Before we begin, let me remind you that our discussions during this conference call will include forward-looking statements relating to, among other things, our expectations concerning the commercialization of LYBALVI, our future financial expectations and business
Alkermes Plc Approval of LYBALVI - Conference Call Transcript
Jun 01, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers